Genetic redundancy in human cervical carcinoma cells: Identification of cells with "normal" properties

International Journal of Cancer

Volumn 120, Issue 10, 2007, Pages 2119-2126

  Bachmann, Anastasia ^a   Zawatzky, Rainer ^a   Rösl, Frank ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Chaotic cell systems; EMCV cytolysis; Human papillomaviruses; Interferon regulation; Oscillation; Redundancy mechanisms; Tumor necrosis factor alpha; Tumorigenicity

Indexed keywords

BETA INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 9; TUMOR NECROSIS FACTOR ALPHA;

ANTIVIRAL ACTIVITY; ARTICLE; CANCER CELL; CARCINOGENICITY; ENCEPHALOMYOCARDITIS VIRUS; EPIGENETICS; FEMALE; HELA CELL; HUMAN; IMMUNE DEFICIENCY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UTERINE CERVIX CARCINOMA;

ANIMALS; AZACITIDINE; BUTYRATES; CARDIOVIRUS INFECTIONS; DNA METHYLATION; ENCEPHALOMYOCARDITIS VIRUS; FEMALE; HELA CELLS; HISTONE DEACETYLASES; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNOCOMPROMISED HOST; INTERFERON REGULATORY FACTOR-1; INTERFERON-BETA; INTERFERON-STIMULATED GENE FACTOR 3, GAMMA SUBUNIT; MICE; MICE, NUDE; PAPILLOMAVIRUS INFECTIONS; TUMOR NECROSIS FACTOR-ALPHA; UTERINE CERVICAL NEOPLASMS;

EID: 34147100520     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22524     Document Type: Article

References (51)

1. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application Nat Rev Cancer 2002;2:342-50.
2. Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer Nat Rev Cancer 2002;2:59-65.
3. Koromilas AE, Li S, Matlashewski G. Control of interferon signaling in human papillomavirus infection. Cytokine Growth Factor Rev 2001;12:157-70.
4. Rösl F, Kleine-Lowinski K, zur Hausen H. The possible role of chemokines in HPV-linked carcinogenesis. In: Rollins BJ, ed. Chemokines and cancer. Totowa, NJ: Humana Press, 1999. 207-25.
5. Mestan J, Digel W, Mittnacht S, Hillen H, Blohm D, Moller A, Jacobsen H, Kirchner H. Antiviral effects of recombinant tumour necrosis factor in vitro. Nature 1986;323:816-19.
6. Bachmann A, Hanke B, Zawatzky R, Soto U, van Riggelen J, zur Hausen H, Rösl F. Disturbance of tumor necrosis factor α-mediated β interferon signaling in cervical carcinoma cells. J Virol 2002;76: 280-91.
7. Taniguchi T, Takaoka A. A weak signal for strong responses: interferon-α/β revisited. Nat Rev Mol Cell Biol 2001;2:378-86.
8. Schneider BL, Kulez-Martin M. Destructive cycles: the role of genomic instability and adaptation in carcinogenesis. Carcinogenesis 2004;25:2033-44.
9. Stanbridge E. Genetic analysis of tumorigenicity in human cell hybrids. Cancer Surv 1984;3:335-50.
10. Hoss A, Zwarthoff EC, Zawatzky R. Differential expression of interferon α and β induced with Newcastle disease virus in mouse macrophage cultures. J Gen Virol 1989;70:575-89.
11. Kawade Y. An analysis of neutralization reaction of interferon by antibody: a proposal on the expression of neutralization titer. J Interferon Res 1980;1:61-70.
12. Khandjian EW, Meric C. A procedure for Northern blot analysis of native RNA. Anal Biochem 1986;159:227-32.
13. Feinberg AP, Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 1983;132:6-13.
14. Iwamura T, Yoneyama M, Yamaguchi K, Suhara W, Mori W, Shiota K, Okabe Y, Namiki H, Fujita T. Induction of IRF-3/-7 kinase and NF-κB in response to double-stranded RNA and virus infection: common and unique pathways. Genes Cells 2001;6:375-88.
15. Soto U, Das BC, Lengert M, Finzer P, zur Hausen H, Rösl F. Conversion of HPV 18 positive non-tumorigenic HeLa-fibroblast hybrids to invasive growth involves loss of TNF-α mediated repression of viral transcription and modification of the AP-1 transcription complex. Oncogene 1999;18:3187-98.
16. Yeung MC, Chang DL, Camantigue RE, Lau AS. Inhibitory role of the host apoptogenic gene PKR in the establishment of persistent infection by encephalomyocarditis virus in U937 cells. Proc Natl Acad Sci USA 1999;96:11860-5.
17. Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol 2000;81:2341-64.
18. Jin YM, Pardoe IU, Burness AT, Michalak TI. Identification and characterization of the cell surface 70-kilodalton sialoglycoprotein(s) as a candidate receptor for encephalomyocarditis virus on human nucleated cells. J Virol 1994;68:7308-19.
19. Kaufman RJ. Double-stranded RNA-activated protein kinase mediates virus-induced apoptosis: a new role for an old actor. Proc Natl Acad Sci USA 1999;96:11693-5.
20. Rueckert RR. Picornaviruses. In: Fields BN, Knipe DM, Howley PM, eds. Virology, 3rd edn. Philadelphia, PA: Lippincott, 1996. 609-54.
21. Meager A. Biological assays for interferons. J Immunol Methods 2002;261:21-36.
22. Ronco LV, Karpova AY, Vidal M, Howley PM. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 1998;12:2061-72.
23. Li S, Labreque S, Gauzzi MC, Cuddihy AR, Wong AH, Pellegrini S, Matlashewski GJ, Koromilas AE. The human papilloma virus (HPV)-18 E6 oncoprotein physically associates with Tyk2 and impairs Jak-STAT activation by interferon-α. Oncogene 1999;18:5727-37.
24. Chen J, Baig E, Fish EN. Diversity and relatedness among the type I interferons. J Interferon Cytokine Res 2004;24:687-98.
25. Agalioti T, Lomvardas S, Parekh B, Yie J, Maniatis T Thanos D. Ordered recruitment of chromatin modifying and general transcription factors to the IFN-β promoter. Cell 2000;103:667-78.
26. Katze MG, He Y Gale M, Jr. Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2002;2:675-87.
27. Sieber OM, Tomlinson SR, Tomlinson IP. Tissue, cell and stage specificity of (epi)mutations in cancers. Nat Rev Cancer 2005;5:649-55.
28. Sato N, Maehara N, Su GH, Goggins M. Effects of 5-aza-2′ deoxycytidine on matrix metalloproteinase expression an pancreatic cancer cell invasiveness. J Natl Cancer Inst 2003;95:327-30.
29. Finzer P, Kuntzen C, Soto U, zur Hausen H, Rösl F. Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression. Oncogene 2001;20:4768-76.
30. Yoneyama M, Suhara W, Fukuhara Y, Fukuda M, Nishida E, Fujiata T. Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J 1998;17:1087-95.
31. Watanabe N, Sakakibara J, Hovanessian AG, Taniguchi T, Fujita T. Activation of IFN-β element by IRF-1 requires a posttranslational event in addition to IRF-1 synthesis. Nucleic Acids Res 1991;19: 4421-8.
32. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70.
33. Coffey DS. Self-organization, complexity and chaos: the new biology for medicine. Nat Med 1998;4:882-5.
34. Vineis P. Cancer as an evolutionary process at the cell level: an epidemiological perspective. Carcinogenesis 2003;24:1-6.
35. Krakauer DC, Plotkin JB. Redundancy, antiredundancy, and the robustness of genomes. Proc Natl Acad Sci USA 2002;99:1405-9.
36. Kitano H. Biological robustness. Nat Rev Genet 2004;5:826-37.
37. Crow JF. The high spontaneous mutation rate: is it a health risk? Proc Natl Acad Sci USA 1997;94:8380-6.
38. Petterson ME, Anderson DI, Roth JR, Berg OG. The amplification model for adaptive mutation: simulations and analysis. Genetics 2005;169:1105-15.
39. Sato M, Taniguchi T, Tanaka N. The interferon system and interferon regulatory factor transcription factors - studies from gene knockout mice. Cytokine Growth Factor Rev 2001;12:133-42.
40. Folkman J, Kalluri R. Cancer without disease. Nature 2004;427:787.
41. Pietrobono R, Pomponi MG, Tabolacci E, Oostra B, Chiurazzi P, Neri G. Quantitative analysis of DNA demethylation and transcriptional reactivation of the FMRI gene in fragile X cells treated with 5-aza-deoxycytidine. Nucleic Acids Res 2002;30:3278-85.
42. Zhang Z, Huettner PC, Nguyen L, Bidder M, Funk MC, Li J, Rader JS. Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer. Oncogene 2006;25:5436-45.
43. Sakamoto S, Potla R, Larner AC. Histone deacetylase activity is required to recruit RNA polymerase II to the promoters of selected interferon-stimulated early response genes. J Biol Chem 2004;279: 40362-7.
44. Genin P, Morin P, Civas A. Impairment of interferon-induced IRF-7 gene expression due to inhibition of ISGF3 formation by trichostatin A. J Virol 2003;77:7113-19.
45. Stelling J, Sauer U, Szallasi Z, Doyle FJ, III, Doyle J. Robustness of cellular functions. Cell 2004;118:675-85.
46. Wagner A. Distributed robustness versus redundancy as causes of mutational robustness. Bioessays 2005;27:176-88.
47. Hata N, Sato M, Takaoka A, Asagiri M, Tanaka N, Taniguchi T. Constitutive IFN-α/β signal for efficient IFN-α/β gene induction by virus. Biochem Biophys Res Commun 2001;285:518-25.
48. Tlsty TD, Margolin BH, Lum K. Differences in the rates of gene amplification in nontumorigenic and tumorigenic cell lines as measured by Luria-Delbrück fluctuation analysis. Proc Natl Acad Sci USA 1989;86:9441-5.
49. Calin GA, Vasilescu C, Negrini M Barbanti-Brodano G. Genetic chaos and antichaos in human cancers. Med Hypotheses 2003;60:258-62.
50. Gatenby RA Vincent TL. An evolutionary model of carcinogenesis. Cancer Res 2003;63:6212-20.
51. Heffner DK. Chaotic tumors and 2 mistakes of molecular oncologists. Ann Diagn Pathol 2005;9:61-7.